Oppenheimer Begins Coverage on OnKure Therapeutics (NASDAQ:OKUR)

Oppenheimer began coverage on shares of OnKure Therapeutics (NASDAQ:OKUR) in a report published on Thursday morning, MarketBeat reports. The brokerage issued an outperform rating and a $35.00 price target on the stock.

OnKure Therapeutics Stock Down 3.1 %

Shares of NASDAQ:OKUR opened at $18.42 on Thursday. The firm has a market capitalization of $61.52 million, a PE ratio of -1.10 and a beta of 0.21. OnKure Therapeutics has a 52 week low of $9.80 and a 52 week high of $86.70.

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.